Sanuwave CEO awarded options for 24,000 shares

SANUWAVE Health reported that Chief Executive Officer and director Morgan C. Frank received a new stock option grant.

Rhea-AI Filing Summary

SANUWAVE Health reported that Chief Executive Officer and director Morgan C. Frank received a new stock option grant. On 01/30/2026, he was awarded options to purchase 24,000 shares of common stock at an exercise price of $26.96 per share, expiring on 01/30/2031.

The options were granted at no cost on the grant date and will vest in four equal installments on the last day of each quarter during 2026, aligning vesting with the company’s quarterly performance periods.

Insider Trade Summary

Grant/Award: 24,000 shares

Grant/Award 1 txn

Insider FRANK MORGAN C.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	24,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 24,000 contracts (Direct)

Footnotes (1)

1. F1. Options will vest in four equal installments on the last day of each quarter during 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SANUWAVE (SNWV) report for Morgan C. Frank?

SANUWAVE reported a stock option grant to CEO Morgan C. Frank. He received options for 24,000 common shares on 01/30/2026, giving him the right to buy shares at $26.96, subject to a 2026 vesting schedule.

What are the key terms of Morgan C. Frank’s new SANUWAVE (SNWV) stock options?

The new stock options let Morgan C. Frank buy 24,000 SANUWAVE shares at $26.96 per share. They were granted on 01/30/2026, cost $0 on grant, and expire on 01/30/2031, providing a long-term equity incentive.

How do Morgan C. Frank’s SANUWAVE (SNWV) options vest in 2026?

The options vest in four equal installments during 2026. Vesting occurs on the last day of each quarter, meaning 25% of the 24,000 options vest at the end of each quarter throughout the year.

How many SANUWAVE (SNWV) derivative securities does Morgan C. Frank hold after this grant?

After the reported transaction, Morgan C. Frank beneficially owns 24,000 derivative securities in the form of stock options. These options represent rights to acquire 24,000 shares of SANUWAVE common stock if he exercises them at $26.96.

Is Morgan C. Frank’s SANUWAVE (SNWV) option grant a purchase or an award?

The filing shows this is an award of stock options, not an open-market share purchase. The transaction code is “A” for acquisition, with a derivative security price of $0, reflecting a compensatory grant by the company.

What roles does Morgan C. Frank hold at SANUWAVE (SNWV) in this filing?

Morgan C. Frank is identified as both a director and Chief Executive Officer of SANUWAVE Health. The Form 4 confirms his status as an officer and director, though he is not marked as a 10% beneficial owner in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRANK MORGAN C.

(Last) (First) (Middle)

9600 W. 76TH STREET

SUITE 118

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SANUWAVE Health, Inc. [ SNVW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$26.96	01/30/2026		A		24,000		(1)	01/30/2031	Common Stock	24,000	$0	24,000	D

Explanation of Responses:

1. Options will vest in four equal installments on the last day of each quarter during 2026.

	/s/ Griffin D. Foster, Attorney-in-Fact for Morgan C. Frank	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.